Abstract 4853: Impact of different therapeutic strategies on survival in laryngeal squamous cell carcinoma (LSCC)

Abstract

Abstract Background: LSCC has seen a rise in cases and deaths over the past 30 years. Considering advancements in the treatment landscape, therapeutic options for patients with LSCC were evaluated to assess their efficacy in improving survival rates. Methods: Data were retrieved from the Surveillance, Epidemiology, and End Results (SEER) (2000-2020) for localized/regional-stage cancer only, including the glottis (GC), supraglottic (SuGC), and subglottic (SC). Patients with a histologically confirmed diagnosis, no other malignancies, and complete data were included. Eight therapeutic groups were identified: surgery (Sx), chemotherapy (CTX), radiotherapy (RT), Sx + adjuvant radiotherapy (ART), Sx + CTX, Sx + RT, Sx + CTX + RT, and CTX + RT. T-tests and chi-square tests were used to compare variables, while Kaplan-Meier, log-rank tests, and Cox regression were used to identify prognostic factors for overall survival (OS) and cancer-specific survival (CSS). Results: 68,282 patients were included (43,434 GC, 24,010 SuGC, and 838 SGC). 12.8% underwent Sx, 0.8% CTX, 0.3% Sx + CTX, 17.1% Sx + ART, 35.3% RT, 1.5% Sx + RT, 5.1% Sx + CTX + RT and 21.5% CTX + RT. 80.8% were males and 63.5% were over 60 years old and white (n=56,171). The median age was 64 years, and median tumor size was 3.2 cm. 36.5% underwent surgery with local tumor excision in 23.9 % and total laryngectomy in 5.7%. White race, regional stage, large tumor size, and CTX were poor prognostic factors for GC. Asian, white race, and total laryngectomy were good prognostic factors for SuGC, whereas male sex and older age were poor prognostic factors. In terms of SCG, Sx + ART was associated with a better prognosis, while regional and white race were associated with a poor prognosis. Conclusion: This study shows survival differences among treatment groups and identifies factors for personalized treatment. It is the first study on all types of laryngeal tumors with a large sample size. Further research is necessary to validate and expand these results. The 5-year survival rates (as a percentage of OS/CSS) for each therapeutic group Cancer Type Sx CTX Sx + CTX RT Sx + RT CTX + RT Sx + CTX + RT Sx + ART GC 91.9/75.5 79.8/77.3 89.2/81.8 89.8/78.1 89.5/85.3 87.8/83 79.1/90.1 90/78.1 SuGC 54.7/56.5 12.9/46.7 25.6/56.2 43.1/51.9 33.5/56.4 45.7/49.7 50.5/59.4 49.3/59.3 SGC 42.2/42.2 75/75 17.7/17.7 53/53 44.4/44.4 47.2/47.2 44.1/41.1 58.7/58.7 Citation Format: Sakhr Alshwayyat, Ayah Erjan, Miassar Rawashdeh, Tala Abdulsalam, Mustafa Alshwayyat. Impact of different therapeutic strategies on survival in laryngeal squamous cell carcinoma (LSCC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4853.